JPS59500317A - 抗ウイルス性組成物 - Google Patents
抗ウイルス性組成物Info
- Publication number
- JPS59500317A JPS59500317A JP57501235A JP50123582A JPS59500317A JP S59500317 A JPS59500317 A JP S59500317A JP 57501235 A JP57501235 A JP 57501235A JP 50123582 A JP50123582 A JP 50123582A JP S59500317 A JPS59500317 A JP S59500317A
- Authority
- JP
- Japan
- Prior art keywords
- virus
- active ingredient
- drug
- composition
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims description 17
- 230000000840 anti-viral effect Effects 0.000 title description 6
- 230000000694 effects Effects 0.000 claims description 19
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical group OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 claims description 17
- XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical compound OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 claims description 15
- 239000004480 active ingredient Substances 0.000 claims description 14
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 8
- 229960005102 foscarnet Drugs 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 5
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Natural products O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 3
- IVSXFFJGASXYCL-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=NC=N[C]21 IVSXFFJGASXYCL-UHFFFAOYSA-N 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- OQHUKLXHSMXZKA-VAOFZXAKSA-N 1-[(2s,4s,5r)-2-ethenyl-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO)O[C@@]1(C=C)N1C(=O)NC(=O)C=C1 OQHUKLXHSMXZKA-VAOFZXAKSA-N 0.000 claims 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 229920002635 polyurethane Polymers 0.000 claims 1
- 239000004814 polyurethane Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 description 43
- 229940079593 drug Drugs 0.000 description 38
- 241000700605 Viruses Species 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 13
- 241001529453 unidentified herpesvirus Species 0.000 description 9
- 230000009467 reduction Effects 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- ODZBBRURCPAEIQ-DJLDLDEBSA-N Brivudine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C=CBr)=C1 ODZBBRURCPAEIQ-DJLDLDEBSA-N 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 208000010201 Exanthema Diseases 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 206010019973 Herpes virus infection Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 108020005202 Viral DNA Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000021186 dishes Nutrition 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000680578 Canid alphaherpesvirus 1 Species 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000230501 Equine herpesvirus sp. Species 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 241000132456 Haplocarpha Species 0.000 description 1
- 208000001688 Herpes Genitalis Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 241001474791 Proboscis Species 0.000 description 1
- 102000005686 Serum Globulins Human genes 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- CNXKXOFTMXPMTH-UAKXSSHOSA-N [1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,4-dioxopyrimidin-5-yl] hypoiodite Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(OI)=C1 CNXKXOFTMXPMTH-UAKXSSHOSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 231100000040 eye damage Toxicity 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 201000004946 genital herpes Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 150000002497 iodine compounds Chemical class 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000968 medical method and process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1982/000182 WO1983002723A1 (en) | 1982-02-12 | 1982-02-12 | Anti-viral compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59500317A true JPS59500317A (ja) | 1984-03-01 |
| JPH0138770B2 JPH0138770B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1989-08-16 |
Family
ID=22167810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57501235A Granted JPS59500317A (ja) | 1982-02-12 | 1982-02-12 | 抗ウイルス性組成物 |
Country Status (9)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4462986A (en) * | 1982-11-04 | 1984-07-31 | Ens Bio Logicals, Inc. | Synergistic anti-herpes compositions |
| IT1170232B (it) * | 1983-10-31 | 1987-06-03 | Anna Gioia Stendardi | Composizioni terapeutiche ad attivita' antivirale |
| WO1992009285A1 (en) * | 1990-11-27 | 1992-06-11 | The Procter & Gamble Company | Combinations of vanilloid compounds and phosphonate antiviral compounds for treatment of herpes infections |
| EP0671918B1 (en) * | 1992-12-03 | 1997-05-28 | Merrell Pharmaceuticals Inc. | Compositions containing acyclovir-like compounds and 2'-vinyl substituted nucleoside analogs for the treatment of viral infections |
| AU2768295A (en) * | 1994-07-11 | 1996-02-09 | Hoechst Marion Roussel, Inc. | Method of treating a neoplastic disease state by conjunctive therapy with 2'-fluoromethylidene derivatives and radiation or chemotherapy |
| CZ284920B6 (cs) * | 1996-02-14 | 1999-04-14 | Vladimír Prof. Mudr. Drsc. Vonka | Preparáty pro léčbu rekurentního herpesu založené na potenciaci účinků syntetických virostatik kofeinem |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3767795A (en) * | 1971-02-25 | 1973-10-23 | Abbott Lab | Method for combating certain virus infection |
| US4199574A (en) * | 1974-09-02 | 1980-04-22 | Burroughs Wellcome Co. | Methods and compositions for treating viral infections and guanine acyclic nucleosides |
| GB1523865A (en) * | 1974-09-02 | 1978-09-06 | Wellcome Found | Purine compunds and salts thereof |
| SE7607496L (sv) * | 1976-07-01 | 1978-01-02 | Astra Laekemedel Ab | Sett for bekempning av virusinfektioner |
-
1982
- 1982-02-12 DE DE8282901187T patent/DE3275061D1/de not_active Expired
- 1982-02-12 JP JP57501235A patent/JPS59500317A/ja active Granted
- 1982-02-12 MC MC82US8200182D patent/MC1585A1/xx unknown
- 1982-02-12 AT AT82901187T patent/ATE24836T1/de not_active IP Right Cessation
- 1982-02-12 WO PCT/US1982/000182 patent/WO1983002723A1/en active IP Right Grant
- 1982-02-12 EP EP82901187A patent/EP0101441B1/en not_active Expired
-
1983
- 1983-02-07 ZA ZA83816A patent/ZA83816B/xx unknown
- 1983-02-14 IT IT8319583A patent/IT1212699B/it active
-
1989
- 1989-09-28 HK HK780/89A patent/HK78089A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0101441B1 (en) | 1987-01-14 |
| HK78089A (en) | 1989-10-06 |
| IT8319583A0 (it) | 1983-02-14 |
| JPH0138770B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1989-08-16 |
| EP0101441A4 (en) | 1985-04-11 |
| DE3275061D1 (en) | 1987-02-19 |
| WO1983002723A1 (en) | 1983-08-18 |
| IT1212699B (it) | 1989-11-30 |
| ATE24836T1 (de) | 1987-01-15 |
| EP0101441A1 (en) | 1984-02-29 |
| MC1585A1 (fr) | 1985-02-22 |
| ZA83816B (en) | 1983-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2342582C (en) | A method of inhibiting formation of infectious herpes virus particles | |
| US4757088A (en) | Antiviral pharmaceutical preparations and methods for their use | |
| CA2992352C (en) | Stuffy nose deblocking composition having antiviral activity | |
| US5484589A (en) | Anti-viral methods using RNAse and DNAse | |
| BG63612B1 (bg) | Състав и метод за профилактика и лечение на нiv идруги инфекциозни заболявания при човека | |
| TW422685B (en) | A pharmaceutical composition for treating viral infections and cancers or tumors | |
| CA1218931A (en) | Anti-viral compositions | |
| JP2724711B2 (ja) | 医薬品生成物 | |
| JPS59500317A (ja) | 抗ウイルス性組成物 | |
| AU2011270096B2 (en) | Agent for suppressing the formation of abnormal skin cells caused by exposure to light | |
| JPS59186985A (ja) | ジメチルアミノメチレン化された抗ヘルペス化合物 | |
| US4499084A (en) | Ara-A Antiviral composition and method of administering the same | |
| US4093716A (en) | Compositions containing 5-amino-5-deoxythymidine and pharmaceutically acceptable salts thereof | |
| Luft | Potent in vivo activity of arprinocid, a purine analogue, against murine toxoplasmosis | |
| CA2465682A1 (en) | Methods of treating leukemia | |
| EP3720440B1 (en) | Treatment of rsv with combination product | |
| GB2207864A (en) | Topical antiviral composition | |
| Corwin et al. | Effect of IUDR and amethopterin on experimental herpes simplex keratitis | |
| JPH0193524A (ja) | ウィルス性疾患の治療薬 | |
| US5002932A (en) | Antiviral pharmaceutical compositions and method of treating herpes | |
| Feldman et al. | Inosiplex for localized herpes zoster in childhood cancer patients: preliminary controlled study | |
| CN104940185A (zh) | 刺芒柄花素的医药用途 | |
| JP2001072597A (ja) | 抗ヘルペスウイルス剤 | |
| TWI764284B (zh) | 使用喹啉化合物來對抗冠狀病毒感染的方法 | |
| CH642543A5 (en) | Medicines with antiviral action |